Mike Catelani Email

President, COO & CFO . Anixa Biosciences

Current Roles

Employees:
15
Revenue:
$2.3M
About
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Anixa Biosciences Address
3150 Almaden Expressway
San Jose, CA
Anixa Biosciences Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.